Regulatory Briefs: Guidance On Distributing Publications On Unapproved Uses; Export Certification Updates

FDA issues a revised draft guidance on distributing scientific publications on unapproved new uses of medical products. The agency enhances its export certification and tracking system. More regulatory news.

FDA issued a draft guidance March 3 to revise a controversial 2009 final guidance on companies distributing scientific and medical publications that address unapproved uses of devices and drugs. The new draft, “Distributing Scientific and Medical Publications on Unapproved New Uses – Recommended Practices” responds to comments received on the 2009 final guidance asking how the guidance would apply to medical textbooks and responds to several citizen petitions. The 2009 guidance, “Good Reprint Practices for the Distribution of Medical Journal Articles and Medical or Scientific Reference Publications on Unapproved New Uses of Approved Drugs and Approved or Cleared Medical Devices,” attracted negative attention on Capitol Hill. (See Also see "FDA Issues Guidance On Off-Label Info; Waxman Seeks ‘Re-examination’" - Medtech Insight, 19 January, 2009..) Comments on the draft are due in early May.

FDA announced Feb. 24 that it has made a series of enhancements to its CDRH Export Certification and Tracking System...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Regulation

New Regulation Significantly Expands eIFU Usage Scope

 

Amendment brings new benefits for device accessories and aesthetic devices used by healthcare professionals.

New EU Rules Limit Chinese Participation In Medtech Procurement

 

From June 30, new European Commission rules will attempt to redress an imbalance in medtech trade between the EU and the People’s Republic of China.

FDA Regulations ‘Lock Out’ Clinically Proven Neuromodulation Devices

 

Flow Neuroscience's neuromodulation headset for the treatment of depression is approved and marketed in the EU. However, two years on, the company is still waiting for US FDA approval despite being assigned breakthrough device designation.

Guidance Details EU Approach On Medtech, AI Regulation Interplay

 

Overlapping clinical testing requirements and decision-making around significant changes to MDAI are among the tricky subjects that the new document explains.

More from Policy & Regulation

FDA Blocks Some Olympus Endoscopes From Entering US

 

After multiple warning letters and safety communications, the US FDA has decided to block the import of certain endoscopes from Olympus. In total, the agency’s action pertains to 58 device models manufactured by the Japanese firm used in urinary, respiratory, abdominal and pelvic procedures.

UK Trails NHS 10-Year Plan With Launch Imminent

 
• By 

Healthcare product industries await publication of the NHS 10-Year Plan, due out the coming days, which will focus on health generally not just the NHS, UK health secretary Wes Streeting said during a final prelaunch event on 24 June.

New EU Rules Limit Chinese Participation In Medtech Procurement

 

From June 30, new European Commission rules will attempt to redress an imbalance in medtech trade between the EU and the People’s Republic of China.